[an error occurred while processing this directive]
临床研究

不同血浆吸附容积在双重血浆分子吸附系统治疗高胆红素血症中的疗效分析

  • 叶慧 ,
  • 雷鸣 ,
  • 许开亮 ,
  • 韩耀国 ,
  • 袁维方 ,
  • 孙玉霞
展开
  • 200137 上海,1上海中医药大学附属第七人民医院重症医学科

收稿日期: 2023-04-24

  修回日期: 2023-08-15

  网络出版日期: 2023-09-28

基金资助

上海市卫健委科研课题青年项目(20194Y0191);浦东新区卫生科研青年项目(PW2020B-3);七院新星(XX2021-13)

The effect of different plasma adsorption volume in the treatment of hyperbilirubinemia using the double plasma molecular adsorption system

  • YE Hui ,
  • LEI Ming ,
  • XU Kai-Liang ,
  • HAN Yao-Guo ,
  • YUAN Wei-Fang ,
  • SUN Yu-Xia
Expand
  • Department of Critical Care Medicine, The Seventh   People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

Received date: 2023-04-24

  Revised date: 2023-08-15

  Online published: 2023-09-28

摘要

目的 观察不同血浆吸附容积在双重血浆分子吸附系统治疗高胆红素血症患者中的临床疗效。 方法 分析于上海中医药大学附属第七人民医院行双重血浆分子吸附系统治疗的40例高胆红素血症患者,根据单次治疗的血浆吸附容积分组,比较各组患者的血常规、凝血功能、C反应蛋白、胆红素清除率等指标。 结果 40例患者共行60次双重血浆分子吸附系统治疗,其中显效4例,有效50例,无效6例,总有效率为90%。单次治疗的血浆吸附容积C组(1.0 L≤血浆吸附容积<1.4 L)或E组(1.8 L≤血浆吸附容积<2.2 L)相较于B组(0.6 L≤血浆吸附容积<1.0 L)胆红素下降率更显著(t=-2.403,P=0.023; t=-2.405,P =0.032)。C组患者治疗后总胆红素差值高于B组(t=-2.068,P=0.048)。治疗后,患者凝血酶原时间和活化部分凝血活酶时间延长(t=-3.662,P=0.001;t=-2.828,P=0.008),国际标准化比值升高(t=-3.092,P =0.004),血浆纤维蛋白原降低(t=4.786,P<0.001),血小板计数减少(t=4.963,P<0.001),C反应蛋白下降(t=3.088,P=0.004)。 结论 双重血浆分子吸附系统单次治疗的血浆吸附容积达到1.0~1.4 L时胆红素的清除效果最具优势,延长吸附柱的治疗时间仍存在一定的吸附能力,可以增加胆红素的清除效率,推荐单次治疗血浆吸附容积为3.5~5.5倍个体血浆容积。

本文引用格式

叶慧 , 雷鸣 , 许开亮 , 韩耀国 , 袁维方 , 孙玉霞 . 不同血浆吸附容积在双重血浆分子吸附系统治疗高胆红素血症中的疗效分析[J]. 中国血液净化, 2023 , 22(10) : 730 -733 . DOI: 10.3969/j.issn.1671-4091.2023.10.003

Abstract

Objective  To observe the clinical effect of different plasma adsorption volume in the treatment of hyperbilirubinemia using the double plasma molecular adsorption system.  Methods  A total of 40 patients with hyperbilirubinemia treated with double plasma molecular adsorption system in the Seventh People's Hospital of Shanghai University of TCM were enrolled in this study. According to the plasma adsorption volume in a single treatment they were divided into groups. Blood routine, coagulation function, C-reactive protein, bilirubin clearance rate and others were compared among groups.  Results  A total of 60 times of double plasma molecular adsorption treatment were performed in the 40 patients, in which 4 times of the treatment were significant effective, 50 times were effective, and 6 times was ineffective, with the total effective rate of 90%. After the treatment, the reduction rate of bilirubin was more significant in the patients using plasma adsorption volume of 1.0~1.4L (group C) or 1.8~2.2L (group E) in a single treatment than in the patients using plasma adsorption volume of 0.6~1.0L (group B) (t=-2.403 and -2.405, P=0.023 and 0.032), and was more significant in group C than in group B (t=-2.068, P=0.048). After the treatment, prothrombin time and activated partial thromboplastin time prolonged (t=-3.662 and -2.828, P=0.001 and 0.008), the international normalized ratio increased (t=-3.092, P=0.004), and plasma fibrinogen (t=4.786, P<0.001), platelet count     (t=4.963, P<0.001) and C-reactive protein decreased (t=3.088, P=0.004).  Conclusion  The double plasma molecular adsorption system reaches the maximum clearance of bilirubin when the plasma adsorption volume ranges between 1.0 to 1.4 L in a single treatment. The efficient of bilirubin clearance can be further increased if the treatment time in the adsorption column is prolonged. It is recommended that the suitable plasma adsorption volume in a single treatment is 3.5~5.5 times of the plasma volume in a patient.

参考文献

[1]黎代强. 双重血浆分子吸附系统(DPMAS)治疗重型肝病新进展[J].中国医学工程, 2015,23(8):198-198.
[2]阮军, 尹恒, 寇国先. 双重血浆分子吸附系统治疗肝衰竭的Meta分析[J]. 中西医结合肝病杂志, 2020,30(5):433-437.
[3]黎春宇, 明全. 双重血浆分子吸附系统联合血浆置换治疗HBV感染相关慢加急性肝衰竭的疗效[J]. 贵州医科大学学报, 2021,46(10):1211-1215.
[4]李新婷,姚瑶,邓家玉,等. 双重血浆分子吸附系统联合半量血浆置换治疗肝衰竭的短期疗效分析[J]. 新疆医科大学学报, 2022, 45(2):155-159.
[5]孔明, 李爽, 耿华, 等. 双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究[J]. 首都医科大学学报, 2021,42(4):647-652.
[6]陈香美. 血液净化标准操作规程[M].北京: 人民军医出版社, 2020 : 230.
[7]刘雷, 朱勇, 胡登科. 双重血浆分子吸附治疗高胆红素血症疗效的相关因素分析[J]. 循证护理,2022,8(7):952-955.
[8]曾湘丽,肖平,周巧玲,等.胆红素吸附治疗高胆红素血症的疗效分析[J].中国现代医学杂志,2019,29(3):110-113.
[9]赵丽娟,陈小兰,柏明,等.胆红素吸附治疗心脏术后高胆红素血症的临床效果[J].心脏杂志,2019,31(5):526-533.
[10]Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34(4):392-398.
[11]闫国胜,李丽丽,姜少利,等.不同吸附剂在双重血浆分子吸附系统治疗肝衰竭中的临床研究[J].中华肝脏病杂志,2019,27(1):51-55.
[12]孙玉霞, 雷鸣, 许开亮, 等. 双重血浆分子吸附系统治疗高胆红素血症的疗效分析[J]. 中国血液净化,2020,19(10):649-652.
[13]李爽,陈煜.血浆紧缺情况下非生物型人工肝治疗新模式的探讨[J].临床肝胆病杂志,2017,33(9):1687-1692.
[14]闫国胜, 李丽丽, 姜少利, 等. 不同吸附剂在双重血浆分子吸附系统治疗肝衰竭中的临床研究[J].中华肝脏病杂志, 2019,27(1):51-55.
[15]钟珊, 王娜, 赵静, 等. 血浆置换联合双重血浆吸附治疗提高慢加急性肝衰竭预后[J].中华肝脏病杂志, 2018,26(10):744-749.
[16]刘雷,董菲,胡登科. 个体化血浆流速对DPMAS治疗肝衰竭合并高胆红素血症病人疗效的影响[J]. 循证护理, 2023,9(7):1269-1272.
[17]周建辉,陈香美,杨云生,等.血浆胆红素吸附时间的探讨[J].军医进修学院学报,2007,28(1):40-41.
[18]裴锋博,龚黎,陈祖君,等.白蛋白透析联合胆红素吸附治疗心脏术后急性肝衰竭临床研究[J].中国血液净化, 2017,16(11):771-773.
文章导航

/

[an error occurred while processing this directive]